Phase-3 Clinical Trial of the Adenosine 2a Antagonist Preladenant, Given as Monotherapy, in Patients with Parkinson’s Disease (S7.004)
Fabrizio Stocchi(San Raffaele University of Rome), David Hewitt(Glasgow Royal Infirmary), Tony W. Ho(Johns Hopkins University), Olivier Rascol(Inserm), Anjela Tzontcheva(Merck & Co., Inc., Rahway, NJ, USA (United States)), Rachel Capece(Merck & Co., Inc., Rahway, NJ, USA (United States)), Susan Huyck(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert A. Hauser(University of South Florida), David Michelson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter Sklar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christopher Lines(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kenneth Wolski(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 6
Related Papers
The Parkinson Progression Marker Initiative (PPMI)
|Progress in Neurobiology|2011|1.9k
Advances in Neuropathic Pain
|Archives of Neurology|2003|1.2k
International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study
|Movement Disorders|2006|1.1k
Sources of variance in 24-hour dietary recall data: implications for nutrition study design and interpretation
|American Journal of Clinical Nutrition|1979|997